A Study of LY2623091 in Participants With High Blood Pressure

Completed · Phase 2 · Has a placebo group

Conditions studied: Primary Hypertension

In brief

The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY2623091 in participants with high blood pressure.

Key facts

Study ID

NCT02194465

Run by

Eli Lilly and Company

People needed

304

Starts

2014-08-01

Expected to finish

2015-03-01

Last updated by the study team

2020-06-26

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have a history of hypertension.
• If participants are naïve to treatment of hypertension, or have not been treated with any antihypertensive medications within the 30 days immediately prior to screening:
• Have seated systolic (SBP) of ≥140 and <170 millimeters of mercury (mmHg) at screening and at the end of the lead-in period.
• If participants are currently being treated for hypertension:
• Are taking a stable dose of 1 or 2 antihypertensive medications for at least the previous 30 days. A combination antihypertensive medication from 2 classes is considered as 2 antihypertensive medications.
• Are willing to discontinue the antihypertensive medications during the study.
• Have seated SBP of ≥140 and <170 mmHg at the end of the lead-in period.
• Have a body mass index (BMI) ≥18.5 and <40 kilograms/m\^2.

You may not qualify if…

• Have a history of severe hypertension (defined as SBP ≥180 mmHg and/or diastolic (DBP) ≥120 mmHg), secondary hypertension, symptomatic postural hypotension, or hospitalization due to hypertension.
• Have SBP ≥180 mmHg and/or DBP ≥110 mmHg at screening, lead-in period, or randomization.
• Have a history of hospitalization due to hyperkalemia, or history of drug discontinuation due to elevated serum potassium levels.
• Have a serum potassium ≤3.5 or >5.0 millimoles per liter (mmol/L).
• Have an estimated glomerular filtration rate (eGFR) <50 milliliters/minute/1.73 m\^2.

Where it is running

• Clinical Research Advantage — Glendale, Arizona, United States
• John Muir Health Network - The Osteoporosis Center — Concord, California, United States
• Encompass Clinical Research — Encinitas, California, United States
• Avail Clinical Research LLC — DeLand, Florida, United States
• Alan Graff, MD, PA — Fort Lauderdale, Florida, United States
• Jacksonville Center for Clinical Research — Jacksonville, Florida, United States
• Cardiovascular Center of Sarasota — Sarasota, Florida, United States
• East West Medical Institute — Honolulu, Hawaii, United States
• Rocky Mountain Diabetes and Osteoporosis Center — Idaho Falls, Idaho, United States
• Northwest Heart Clinical Research, LLC — Arlington Heights, Illinois, United States
• Cedar-Crosse Research Center — Chicago, Illinois, United States
• Midwest Institute for Clinical Research — Indianapolis, Indiana, United States
• Community Clinical Research Center — Muncie, Indiana, United States
• Heartland Research Associates — Wichita, Kansas, United States
• Grace Research — Bossier City, Louisiana, United States
• Maine Research Associates — Auburn, Maine, United States
• AB Clinical Trials — Las Vegas, Nevada, United States
• Rochester Clinical Research, Inc. — Rochester, New York, United States
• Metrolina Internal Medicine, P.A. — Charlotte, North Carolina, United States
• PharmQuest — Greensboro, North Carolina, United States
• Lillestol Research LLC — Fargo, North Dakota, United States
• Sterling Research Group, LTD — Cincinnati, Ohio, United States
• Rapid Medical Research Inc — Cleveland, Ohio, United States
• Columbus Clinical Research — Columbus, Ohio, United States
• Dayton Clinical Research — Dayton, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.